ATE297730T1 - Nasenspray enthaltend ondansetron-hydrochlorid - Google Patents

Nasenspray enthaltend ondansetron-hydrochlorid

Info

Publication number: ATE297730T1
Authority: AT; Austria
Prior art keywords: weight; antiemetic; ondansetron hydrochloride; cyclodextrin; beta
Prior art date: 2001-04-20

Application number

AT02252717T

Other languages

English (en)

Inventor

Jin Auh

Chang Hwan Kim

In Koo Chun

Original Assignee

Ahn Gook Pharma Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-20

Filing date

2002-04-17

Publication date

2005-07-15

2002-01-11 Priority claimed from KR10-2002-0001758A external-priority patent/KR100434390B1/ko

2002-04-17 Application filed by Ahn Gook Pharma Co Ltd filed Critical Ahn Gook Pharma Co Ltd

2005-07-15 Application granted granted Critical

2005-07-15 Publication of ATE297730T1 publication Critical patent/ATE297730T1/de

Links

MKBLHFILKIKSQM-UHFFFAOYSA-N 9-methyl-3-[(2-methyl-1h-imidazol-3-ium-3-yl)methyl]-2,3-dihydro-1h-carbazol-4-one;chloride Chemical compound Cl.CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 MKBLHFILKIKSQM-UHFFFAOYSA-N 0.000 title abstract 3
229960000770 ondansetron hydrochloride Drugs 0.000 title abstract 3
239000007921 spray Substances 0.000 title 1
230000003474 anti-emetic effect Effects 0.000 abstract 3
239000002111 antiemetic agent Substances 0.000 abstract 3
239000004480 active ingredient Substances 0.000 abstract 2
239000000463 material Substances 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
229920000858 Cyclodextrin Polymers 0.000 abstract 1
239000001116 FEMA 4028 Substances 0.000 abstract 1
239000002202 Polyethylene glycol Substances 0.000 abstract 1
229960000686 benzalkonium chloride Drugs 0.000 abstract 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 abstract 1
235000011175 beta-cyclodextrine Nutrition 0.000 abstract 1
229960004853 betadex Drugs 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
239000007922 nasal spray Substances 0.000 abstract 1
229940097496 nasal spray Drugs 0.000 abstract 1
229920001223 polyethylene glycol Polymers 0.000 abstract 1
159000000000 sodium salts Chemical class 0.000 abstract 1
239000002904 solvent Substances 0.000 abstract 1
229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 abstract 1
ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Otolaryngology (AREA)
Inorganic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hospice & Palliative Care (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT02252717T 2001-04-20 2002-04-17 Nasenspray enthaltend ondansetron-hydrochlorid ATE297730T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
KR20010021573		2001-04-20
KR10-2002-0001758A KR100434390B1 (ko)	2001-04-20	2002-01-11	1,2,3,9-테트라히드로-9-메틸-3-[(2-메틸-1ｈ-이미다졸-1-일)메틸]-4ｈ-카바졸-4-온을 유효성분으로 하는 비강분무용조성물

Publications (1)

Publication Number	Publication Date
ATE297730T1 true ATE297730T1 (de)	2005-07-15

Family

ID=36217590

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02252717T ATE297730T1 (de)	2001-04-20	2002-04-17	Nasenspray enthaltend ondansetron-hydrochlorid

Country Status (6)

Country	Link
US (1)	US20030044356A1 (de)
EP (1)	EP1250925B1 (de)
JP (1)	JP4152118B2 (de)
AT (1)	ATE297730T1 (de)
DE (1)	DE60204620T2 (de)
ES (1)	ES2244726T3 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0328186D0 (en) *	2003-12-05	2004-01-07	West Pharm Serv Drug Res Ltd	Intranasal compositions
GB0329918D0 (en) *	2003-12-24	2004-01-28	West Pharm Serv Drug Res Ltd	Intranasal compositions
US20060045850A1 (en) *	2004-08-30	2006-03-02	Qpharma, Llc	Nasal delivery of cyclodextrin complexes of anti-inflammatory steroids
RU2009127890A (ru) *	2007-01-17	2011-02-27	Девирэкс Аг (Ch)	Составы, содержащие циклодекстрины
US20130213393A1 (en)	2009-12-22	2013-08-22	Evoke Pharma, Inc.	Nasal formulations of metoclopramide
JP5955767B2 (ja) *	2009-05-20	2016-07-20	インセルム（インスティチュートナショナルデラサンテエデラリシェルシェメディカル）	損傷性前庭障害の処置における使用のためのセロトニン５−ｈｔ３受容体拮抗薬
US20110207764A1 (en) *	2010-02-23	2011-08-25	Valery Alakhov	Cyclopolysaccharide compositions
US20110288115A1 (en) *	2010-05-24	2011-11-24	Avmedis Llc	Treatment of vagally-mediated spectrum disorders
US8383663B2 (en)	2010-07-19	2013-02-26	Supratek Pharma Inc.	Bendamustine anionic-catioinic cyclopolysaccharide compositions
CN103957707A (zh) *	2011-08-25	2014-07-30	伊沃克制药公司	与女性胃轻瘫有关的症状的治疗
DE102013001151A1 (de)	2013-01-24	2014-07-24	Merz Pharma Gmbh & Co. Kgaa	Sprühbare flüssige Zubereitung zur insbesondere nasalen Anwendung mit erhöhter lokaler Verweilzeit
DE202013000748U1 (de)	2013-01-24	2013-02-19	Merz Pharma Gmbh & Co. Kgaa	Sprühbare flüssige Zubereitung zur insbesondere nasalen Anwendung mit erhöhter lokaler Verweilzeit
PL2759290T3 (pl)	2013-01-24	2020-03-31	Merz Pharma Gmbh & Co. Kgaa	Płynny preparat w aerozolu do stosowania donosowego z wydłużonym miejscowym czasem działania
US9050325B2 (en) *	2013-04-08	2015-06-09	Abdul Zahir	Ondansetron nasal spray composition
EP3160444B1 (de) *	2014-06-25	2021-11-24	Synergia Bio Sciences Private Limited	Pharmazeutische öl-in-wasser-nanoemulsion
US20160206610A1 (en) *	2015-01-20	2016-07-21	Xoc Pharmaceuticals, Inc.	Methods for treating and/or preventing emesis and/or nausea including acute and/or delayed nausea and/or acute emesis and/or delayed emesis
SI3442537T1 (sl)	2016-04-14	2024-05-31	Sensorion	(+)-azasetron za uporabo pri zdravljenju ušesnih obolenj
EP3554489A4 (de)	2016-12-15	2020-06-17	Evoke Pharma, Inc.	Behandlung von mässiger bis schwerer gastroparese
CN113559277B (zh) *	2018-01-11	2023-11-17	比卡生物科技（广州）有限公司	一种注射用卡巴他赛组合物及其制备方法
US12414914B2 (en)	2018-07-25	2025-09-16	Bika Biotechnology (Guangzhou) Co., Ltd	Docetaxel composition for injection and preparation method therefor
GB202301322D0 (en)	2023-01-30	2023-03-15	Therakind Ltd	Antiemetic pharmaceutical compositions for nasal delivery

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL8701682A (nl) *	1986-07-30	1988-02-16	Sandoz Ag	Werkwijze voor het therapeutisch toepassen van serotonine antagonisten, aktieve verbindingen en farmaceutische preparaten die deze verbindingen bevatten.
GB9202464D0 (en) *	1992-02-05	1992-03-18	Danbiosyst Uk	Composition for nasal administration
US5897858A (en) *	1994-02-03	1999-04-27	Schering-Plough Healthcare Products, Inc.	Nasal spray compositions exhibiting increased retention in the nasal cavity
US5576311A (en) *	1994-11-30	1996-11-19	Pharmos Corporation	Cyclodextrins as suspending agents for pharmaceutical suspensions
US5688955A (en) *	1996-03-08	1997-11-18	Adolor Corporation	Kappa agonist compounds and pharmaceutical formulations thereof
US20030095927A1 (en) *	1997-10-01	2003-05-22	Dugger Harry A.	Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
CA2371822A1 (en) *	1999-03-01	2000-09-08	Sepracor Inc.	Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
WO2000074651A1 (de) *	1999-06-02	2000-12-14	Hexal Ag	Pharmazeutische zusammensetzung zur nasalen anwendung von wasserunlöslichen und/oder schwer wasserlöslichen wirkstoffen
US6780825B2 (en) *	2001-02-06	2004-08-24	Playtex Products, Inc.	Cleansing compositions with milk protein and aromatherapy

2002
- 2002-04-02 US US10/114,691 patent/US20030044356A1/en not_active Abandoned
- 2002-04-09 JP JP2002106961A patent/JP4152118B2/ja not_active Expired - Fee Related
- 2002-04-17 EP EP02252717A patent/EP1250925B1/de not_active Expired - Lifetime
- 2002-04-17 ES ES02252717T patent/ES2244726T3/es not_active Expired - Lifetime
- 2002-04-17 AT AT02252717T patent/ATE297730T1/de active
- 2002-04-17 DE DE60204620T patent/DE60204620T2/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JP4152118B2 (ja)	2008-09-17
JP2002356424A (ja)	2002-12-13
ES2244726T3 (es)	2005-12-16
EP1250925A2 (de)	2002-10-23
US20030044356A1 (en)	2003-03-06
EP1250925B1 (de)	2005-06-15
EP1250925A3 (de)	2003-11-26
DE60204620D1 (de)	2005-07-21
DE60204620T2 (de)	2006-05-11

Legal Events

Date

Code

Title

Description

2006-02-15

UEP

Publication of translation of european patent specification

Ref document number: 1250925

Country of ref document: EP

Publication	Publication Date	Title
ATE297730T1 (de)	2005-07-15	Nasenspray enthaltend ondansetron-hydrochlorid
CY1106522T1 (el)	2012-01-25	Ετepοκυκλικη ενωση και αντικαρκινικο μεσο που πepιεχει την ιδια ως δραστικο συστατικο
BR0003365A (pt)	2001-09-18	Composições farmacêuticas
CY1107850T1 (el)	2013-06-19	Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
ES2193208T3 (es)	2003-11-01	Nuevos derivados de quinuclidina y composicion farmaceutica que los contiene.
IS8502A (is)	2006-06-08	Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
IS2310B (is)	2007-11-15	Nefholssamsetning úr rótigótíni
NO2010023I1 (no)	2010-12-14	Vernakalant eller et solvat eller farmasøytisk akseptabelt salt derav, herunder inkludert vernakalanthydroklorid
EP1389137A4 (de)	2005-01-05	Zusammensetzungen für die freisetzung von protein auf dem pulmonalen weg
JP2001187728A (ja)	2001-07-10	眼科用組成物
ATE271383T1 (de)	2004-08-15	Pulverformulierung zur inhalation
ATE376423T1 (de)	2007-11-15	Gelierende wässrige pharmazeutische zusammensetzungen
DE69635996D1 (de)	2006-05-18	Pharmazeutische zusammensetzungen mit hydroximsäurederivaten
SE0402762D0 (sv)	2004-11-11	Indazole sulphonamide derivatives
DE60015173D1 (de)	2004-11-25	Verbindung mit wachstumshormon-freisetzenden eigenschaften
JP3846537B2 (ja)	2006-11-15	コンタクトレンズ用装着液
WO2006118948A3 (en)	2007-05-18	Therapeutic compositions
BR0013793A (pt)	2002-05-14	Medicamentos profiláticos e terapêuticos para doenças oftálmicas
PT992509E (pt)	2004-12-31	Novos derivados macrolidos
ATE497764T1 (de)	2011-02-15	Perkutane absorptionszubereitungen mit 3-methyl-1-phenyl-2-pyrazolin-5-on
TW201720450A (zh)	2017-06-16	眼科組成物
JP5092138B2 (ja)	2012-12-05	コンタクトレンズ装着液
HU0102987D0 (en)	2001-09-28	Pharmaceutical composition for treating parkinson's disease comprising astrocyte function-improving agent as active ingredient
CA2529860A1 (en)	2004-12-29	Ophthalmic composition
JP2001354592A (ja)	2001-12-25	点眼剤